Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
- About
AC Immune Ltd(ACIU)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ACIU
09/15/2026: ACIU (1-star) has a low Upturn Star Rating. Not recommended to BUY.
AC Immune is a clinical-stage biotechnology company developing precision medicines for neurodegenerative diseases like Alzheimer's. Its primary strength lies in its proprietary technology platforms and its ability to secure major strategic partnerships, which validate its research. The company's investment story centers on the success of its vaccine candidates and diagnostic tools. Key risks include the inherent volatility of clinical trial outcomes, financial reliance on partners, and fierce competition from larger pharmaceutical firms. As a high-risk biotech stock, it is most suited for growth-oriented investors who can tolerate significant volatility, while progress in its pipeline remains the most critical development to monitor.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | This is a high-risk, high-reward play suitable for those focused on clinical development milestones. |
| Momentum investor | Mixed fit | The stock often reacts strongly to clinical news, making it a potential, though volatile, momentum candidate. |
| Value investor | Weak fit | The lack of consistent earnings and product revenue makes traditional value metrics inapplicable. |
| Dividend investor | Weak fit | The company does not pay dividends and focuses entirely on capital reinvestment. |
| Low-risk investor | Weak fit | High clinical and financial risks make this unsuitable for conservative, risk-averse portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical trial results can cause significant swings in stock price. |
| Valuation risk | Medium / high | Valuation is highly speculative and dependent on future pipeline success. |
| Competition risk (Large Pharma) | High | Well-funded competitors can out-spend and potentially outperform in drug development. |
| Business quality | Medium | While the technology is advanced, the lack of commercial revenue limits financial robustness. |
| Dividend income | Low / none | Investors should expect zero income from dividends. |
| Execution risk | High | The success of the company rests on navigating complex, high-failure clinical trial environments. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -32.99% | Avg. Invested days 22 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 264.48M USD | Price to earnings Ratio - | 1Y Target Price 8.43 |
Price to earnings Ratio - | 1Y Target Price 8.43 | ||
Volume (30-day avg) 204.7K shares | Beta 1.59 | 52 Weeks Range 2.10 - 4.00 | Updated Date 09/15/2026 |
52 Weeks Range 2.10 - 4.00 | Updated Date 09/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.52 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Research Collaborations | Upfront payments, research funding, and milestone payments from partners. | The company earns money by partnering its drug candidates with big pharmaceutical companies. |
| Diagnostic Licensing | Licensing fees for Tau-PET tracer technology. | Revenue is generated by allowing others to use their proprietary imaging diagnostic tools. |
Valuation
Trailing PE - | Forward PE 16.23 | Enterprise Value 177.23M | Price to Sales(TTM) 15.11 |
Enterprise Value 177.23M | Price to Sales(TTM) 15.11 | ||
Enterprise Value to Revenue 8.68 | Enterprise Value to EBITDA -0.76 | Shares Outstanding 99.43M | Shares Floating 39.19M |
Shares Outstanding 99.43M | Shares Floating 39.19M | ||
Percent Insiders 37.9 | Percent Institutions 24.45 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About AC Immune Ltd
Exchange NASDAQ | Headquarters - | ||
IPO Launch date 2016-09-23 | Interim CEO & Chairman of the Board Dr. Martin Zugel M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 90 | Website https://www.acimmune.com |
Full time employees 90 | Website https://www.acimmune.com | ||
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti-Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome related AD; ACI-7104.056 to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. In addition, it develops diagnostic programs consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589 and ACI-15916, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative diseases. Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD; Morphomer a-syn to compete with small molecule inhibitors of a-syn aggregation; and NeuroOrphan Tauopathies. Additionally, it generates discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.